British drugmaker AstraZeneca (LSE: AZN) has successfully expanded the labels for Farxiga (dapagliflozin) and Xigduo XR (dapagliflozin/metformin) in the USA to cover a new population of people with with type 2 diabetes (T2D) and moderate kidney impairment.
The updated labels lower the eGFR threshold for treatment, thereby expanding the group of people that can potentially be treated.
Farxiga is indicated together with diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Xigduo XR is indicated for the same population, when treatment with both dapagliflozin and metformin is appropriate.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze